Epigenomics AG: Chief Executive Officer Greg Hamilton Resigns
|
EQS-News: Epigenomics AG
/ Key word(s): Personnel
Epigenomics AG: Chief Executive Officer Greg Hamilton Resigns Berlin (Germany), April 12, 2023 - The Chief Executive Officer of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), Greg Hamilton, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective June 30, 2023. Between now and the resignation date Greg Hamilton will continue to lead the Company’s restructuring efforts in coordination with the Supervisory Board. The Company is committed to maximizing the value of its technology through corporate partnering, licensing and/or asset sales. Dr. Helge Lubenow, Chairman of the Supervisory Board of Epigenomics AG, thanked Greg Hamilton on behalf of the entire Supervisory Board: “Greg Hamilton has taken a leading role in the commercialization of Epi ProColon and the development of the "Next-Gen" colorectal cancer screening test over the last years and has driven the process with his experience and strategic vision." Greg Hamilton has been CEO of Epigenomics AG since July 2016 and in his role has been instrumental in working with the Centers for Medicare and Medicaid Services (CMS) to establish clear reimbursement requirements for future blood-based colorectal cancer tests. However, in recent months, in the current capital market environment, the Company has been unable to raise additional capital to secure funding for the FDA pivotal study of the "Next-Gen" test. In response, the restructuring of the Company was initiated on February 15, 2023 to minimize costs. Against this backdrop, the resignation of Greg Hamilton now also takes place. Furthermore, talks are being initiated with the other members of the Executive Board regarding the future composition of the board in the light of the restructuring of the company.
About Epigenomics Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer. Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics develops blood tests for various cancer indications with high unmet medical need. Epigenomics currently focuses on the further development of its blood test Epi proColon® “Next-Gen” for the early detection of colorectal cancer. For further information please visit www.epigenomics.com.
Contact: Investor Relations
This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.
12.04.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Epigenomics AG |
| Geneststraße 5 | |
| 10829 Berlin | |
| Germany | |
| Phone: | +49 30 24345-0 |
| Fax: | +49 30 24345-555 |
| E-mail: | ir@epigenomics.com |
| Internet: | www.epigenomics.com |
| ISIN: | DE000A32VN83 |
| WKN: | A32VN8 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1606317 |
| End of News | EQS News Service |
|
|
1606317 12.04.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.